GSK Opens New Respiratory Manufacturing Facility

Article

The facility located in Ware, UK, will be used to manufacture GSK’s Ellipta inhaler.

GlaxoSmithKline (GSK) opened a £56 million (approximately $80.67 million) manufacturing facility in Ware, United Kingdom, according to an April 18, 2016 press announcement. The 4200-m2 facility will create 150 new jobs in the UK.

The Ware facility is the latest expansion of GSK’s Ellipta inhaler manufacturing. The company says they expect the opening of the facility to nearly double production of Ellipta inhalers to at least 37 million per year by 2017, 95% of which, the company said, will be exported.

Since 2013, over 400 roles will have been created at the manufacturing site in Ware, bringing the staff total to 1200, GSK said. This includes over 30 apprentice and 50 graduate roles.

Source: GlaxoSmithKline

 

Recent Videos
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
© 2024 MJH Life Sciences

All rights reserved.